![]() MediWound MediWound is a biotechnology company engaged in developing innovative solutions in severe burn and chronic wound care. | ![]() Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | ![]() Alexion Pharmaceuticals Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases. | |
Founding Date | Founding Date 2001 | Founding Date N/A | Founding Date 1992 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Yavne, IL HQ Rüsselsheim Am Main, DE Wilmington, US | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Boston, US HQ Frenchs Forest, AU Wien, AT Elsene, BE São Paulo, BR Vaughan, CA Shanghai, CN see more |
Employees | Employees 111 | Employees 29723% increase | Employees 10,6006% increase |
Valuation ($) | Valuation ($) 196.3 m | Valuation ($) 1.1 b | Valuation ($) 40.3 b |
Financial | |||
Revenue (est.) | Revenue (est.) $17m (FY, 2025) | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) $6.1b (FY, 2020) |
Cost of goods | Cost of goods $13.1m (FY, 2025) | Cost of goods N/A | Cost of goods $553.5m (FY, 2020) |
Gross profit | Gross profit $4.1m (FY, 2025) | Gross profit €53m (FY, 2025) | Gross profit $5.5b (FY, 2020) |
Net income | Net income ($23.9m) (FY, 2025) | Net income (€196.4m) (FY, 2025) | Net income $603.4m (FY, 2020) |

Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company
Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases.
View company